Medical Writing Support for Fast Track and Priority Review Submissions

Published on 24/12/2025

Step-by-Step Medical Writing Guide for Fast Track and Priority Review Submissions

Fast track and priority review designations provide pharmaceutical companies with expedited pathways to bring promising therapies to patients faster. For medical writers, this means condensing complex clinical and regulatory narratives into precise, high-impact documents under compressed timelines. This tutorial outlines how to provide effective medical writing support during fast track and priority review regulatory submissions, especially for FDA, EMA, and other global agencies.

Table of Contents

Understand Fast Track and Priority Review Designations:

These expedited programs are granted by regulatory authorities to accelerate the review of drugs for serious conditions or unmet medical needs. As per USFDA guidance:

Fast Track: Enables rolling submission and early interactions with FDA
Priority Review: Shortens review time from 10 months to 6 months for NDA/BLA

EMA and other agencies have similar mechanisms (e.g., PRIME in Europe). Medical writers must understand these regulatory expectations to align submission content and schedules.

Start Early and Define Submission Strategy:

Engage early in cross-functional meetings to understand the regulatory pathway and timelines. Document support needs may include:

Pre-NDA/BLA meeting briefing books
Fast Track designation requests
Rolling module submissions
Accelerated clinical study reports (CSRs)
Risk management planning and labeling documents

Medical writers

must coordinate with regulatory, clinical, and biostatistics teams to align data readiness and submission targets.

Manage Rolling Submissions and Module Prioritization:

Fast Track designation allows sponsors to submit components of the marketing application as they become ready (rolling submission). Writers must prepare:

Module 2: Summaries and overviews (clinical, non-clinical)
Module 5: Clinical study reports with appendices
Module 3: CMC sections in collaboration with technical writers

Each module must be submission-ready and appropriately referenced, even if submitted separately. Align terminology, cross-references, and formatting across modules.

Authoring CTD Documents Under Expedited Timelines:

CTD documents needed for priority submissions include:

Clinical Overview (Module 2.5)
Summary of Clinical Efficacy and Safety (Modules 2.7.3 and 2.7.4)
Individual CSRs and integrated summaries
Benefit-risk evaluations

Use pre-approved templates and pharma SOPs to maintain structure and consistency. Apply concise language, consistent terminology, and risk-based reasoning throughout.

Writing the Fast Track Designation Request:

This request must include compelling evidence that the product:

Treats a serious condition
Demonstrates potential to address unmet medical needs

Medical writers should provide a strong narrative with supporting data, clinical rationale, and references. Include citations from relevant literature and early-phase data summaries.

Tips for Accelerated Medical Writing Processes:

Use real-time writing with simultaneous review cycles
Align with project management tools to track document progress
Build annotated templates with regulatory reference points
Keep a library of data cut-off points, interim analysis notes, and CSR templates
Maintain collaboration with stability testing teams for integrated reporting

All documents must align with the product’s GMP compliance status and submission-readiness.

Responding to Agency Queries Quickly:

Expedited pathways mean quicker feedback cycles from regulatory agencies. Writers must support:

Q&A documents for IR (Information Requests)
Briefing packages for advisory meetings
Submission amendments or clarifications

Follow your organization’s validation master plan to ensure consistency in references, especially for clinical validation or assay results.

Common Mistakes in Fast Track Submissions:

Incomplete cross-referencing between modules
Data discrepancies due to last-minute updates
Inadequate justification for expedited designation
Non-compliance with eCTD format specifications
Using legacy content not aligned with current data cut-off

Avoid such pitfalls by using structured medical writing processes and documentation review plans.

Best Practices for Writers in Expedited Pathways:

Establish pre-approved content blocks for reuse
Use version control tools to manage iterative drafts
Set up peer reviews for high-priority documents
Engage statisticians early for aligned efficacy narratives
Maintain global pharma regulatory compliance across regions

Focus on clear, impactful writing that supports the urgency and clinical importance of the drug.

Conclusion:

Medical writing for fast track and priority review submissions requires efficiency, regulatory awareness, and strategic content development. By understanding the expectations of agencies like USFDA and EMA, writers can create accurate and persuasive documents that support expedited review pathways.

Use rolling submissions, writing templates, and real-time collaboration as tools to meet tight timelines while ensuring document quality and compliance. The medical writer is a key player in fast-tracking innovation to patients — your role is as much strategic as it is technical.